Dec. 26 at 9:47 PM
$AQST From AI:
While no official acquisition has been announced, there is market speculation and analyst opinion suggesting several major pharmaceutical companies might be interested in Aquestive Therapeutics (AQST), primarily due to its potential blockbuster product, Anaphylm.
Companies mentioned in market speculation as potential acquirers include:
Viatris: Some market observers believe Viatris, which has a significant global presence in the epinephrine market (via the EpiPen), would be a strong strategic fit and is likely aware of Anaphylm's potential.
Novartis: Novartis has been mentioned in broader biopharma takeover speculation as a possible acquirer of Aquestive, among other small biotechs.
Amgen: Similar to Novartis, Amgen has been speculated as a potential acquirer, though these discussions were reportedly around higher price points in the past.
Aquestive's CEO has mentioned "across the board" interest from strategic parties in the company's technology platform.
